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Phthalates are important industrial chemicals
used in the manufacture of a wide range of
plastic and nonplastic products and can be
divided into two basic groups: those used as
plasticizers for synthetic polymers that are
incorporated into food wrap, medical tubing,
and molded toys, and those used primarily in
consumers products such as varnishes, per-
fumes, nail polishes, and insect repellents. It
is conceivable that the route of exposure of
an organism to phthalates is an important
parameter when considering metabolism of
these chemicals in vivo. Phthalates are readily
metabolized in the gut, such that oral expo-
sure would not lead to accumulation of high
concentrations of these chemicals (1).
However, few data are available on the
metabolism of this group of chemicals after
inhalation or dermal exposure. The primary
route of phthalate exposure to the general
human population has been presumed to be
ingestion. Lower molecular-weight phthalates
such as diethyl phthalate (DEP) and di-n-
butyl phthalate (DBP) can be absorbed per-
cutaneously, and the more volatile congeners
can be inhaled. Dermal absorption is impor-
tant for products applied to skin.
Blount et al. (2) reported the concentra-
tions of seven phthalate monoesters
[monoethyl phthalate (MEP), monobutyl
phthalate (MBP), monobenzyl phthalate
(MBzP), monocyclohexyl phthalate (MCHP),
mono-2-ethylhexyl phthalate (MEHP),
monooctyl phthalate (MOP), monoisononyl
phthalate (MINP)] in the urine of 289 peo-
ple, providing the first systematic compila-
tion of data that address phthalate exposures
to the general population from commercially
important phthalate diesters. Kohn et al. (3)
applied a simple pharmacokinetic model to
estimate the total daily intake of phthalates
that would result in the reported urinary
concentrations of monoester metabolites.
These intake estimates were used as a mea-
sure of total exposure to diethyl phthalate
(DEP), di-n-butyl phthalate (DBP), n-butyl
benzyl phthalate (BBP), dicyclohexyl phtha-
late (DCHP), di-(2-ethylhexyl) phthalate
(DEHP), di-n-octyl phthalate (DOP), di-i-
nonyl phthalate (DINP).
Blount et al. (2) reported a considerable
number of observations in which the analyte
levels in urine were below the limit of detec-
tion (LOD) for the procedure being used.
This analysis excluded analytes for which
more than 25% of the studied individuals
were below the LOD and discarded indi-
viduals below the LOD for analytes they
did analyze. This represents a substantial
loss of information. Maximum likelihood
methods for censored observations (4–7)
have been used for many years to analyze
survival data and data for which some
observations cannot be seen, but it is
known that the observation is beyond some
critical point. For urinary metabolite data,
an observation below the LOD can be
assumed to have a metabolite concentration
less than the LOD. Methods have been
developed for analyzing biomarkers of
exposure—including observations below
the LOD—by using statistical likelihoods
and regression methods for censored data
(8). Using a likelihood for censored data,
these fractional pieces of information con-
tribute to the overall interpretation of the
data and can be used in a natural frame-
work to estimate parameters and test for
population differences. To account for
strata differences of demographic factors,
we estimated population-based exposures to
phthalates using a weighted analysis in
which weights were assigned for each indi-
vidual group depending on the frequency
of their demographic variables in the gen-
eral U.S. population.
The aim of this study was to present
methods for the analysis of exposure esti-
mates based on urinary biomarker data
accounting for strata differences and prob-
lems with LOD and to investigate the associ-
ation between biomarker-based exposure
estimates for phthalates and demographic
factors in a human reference population.
Materials and Methods
Phthalates data. The data for this study were
collected from adults during 1988–1994 as
part of the Third National Health and
Nutritional Examination Survey (NHANES
III) (9). NHANES III analyzed urine
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Population-based estimates of environmental exposures using biomarkers can be difficult to
obtain for a variety of reasons, including problems with limits of detection, undersampling of key
strata, time between exposure and sampling, variation across individuals, variation within individ-
uals, and the ability to ﬁnd and interpret a given biomarker. In this article, we apply statistical
likelihoods, weighted sampling, and regression methods for censored data to the analysis of bio-
marker data. Urinary metabolites for seven phthalates, reported by Blount et al., are analyzed
using these methods. In the case of the phthalates data, we assumed the underlying model to be a
log-normal distribution with the mean of the distribution deﬁned as a function of a number of
demographic variables that might affect phthalate levels in individuals. Included as demographic
variables were age, sex, ethnicity, residency, family income, and education level. We conducted
two analyses: an unweighted analysis where phthalate distributions were estimated with changes
in the means of these distributions as a function of demographic variables, and a weighted predic-
tion for the general population in which weights were assigned for a subset of the population
depending on the frequency of their demographic variables in the general U.S. population. We
used statistical tests to determine whether any of the demographic variables affected mean phtha-
late levels. Individuals with only a high school education had higher levels of di-n-butyl phthalate
than individuals with education beyond high school. Subjects who had family income less than
$1,500 in the month before sampling and/or only high school education had higher levels of n-
butyl benzyl phthalate levels than other groupings. Di(2-ethylhexyl) phthalate was higher in
males and/or in urban populations and/or in people who had family income less than $1,500 per
month. Our findings suggest that there may be significant demographic variations in exposure
and/or metabolism of phthalates and that health-risk assessments for phthalate exposure in
humans should consider different potential risk groups. Key words: demographic factors, phtha-
lates, risk assessment. Environ Health Perspect 110:405–410 (2002). [Online 11 March 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p405-410koo/abstract.htmlsamples from 289 subjects for 7 phthalate
monoesters (MEP, MBP, MBzP, MCHP,
MEHP, MOP, MINP). Urine samples were
collected at different times throughout the day
and were not ﬁrst-morning voids. This sam-
pling of the NHANES III population was not
designed to be representative of the U.S. pop-
ulation but rather to serve as a reference range
for a demographically described group. The
population studied comprised noninstitution-
alized adults ages 20–60 years (mean ± SD,
37.4 ± 10.6 years). The sex distribution (56%
female) was similar across age groups. Racial
distribution was weighted toward minority
groups (Caucasian, 39%; African American,
30%; Mexican American, 23%; and other,
8%). The residency distribution was urban
57%, rural 43%. The family income was cate-
gorized by two groups (≥ $1,500 in the month
before sampling, 56%; < $1,500 in the month
before sampling, 44%), and the education
level was categorized by two groups (high
school diploma or less, 69%; education
beyond high school, 31%).
Estimating intake levels from urinary
metabolites. Kohn et al. (3) calculated the
intake for each individual in the reference
population as follows: The daily exposure
can be estimated by using a linear two-com-
partment model. The normalized integrated
rate equations are 
FE = 1 – exp (–ktotal t) [1]
[2] 
where FE and FU are the total and urinary
fractions of the dose eliminated in time t,
and ktotal and ku are the apparent ﬁrst-order
rate constants for total elimination and elim-
ination of urinary monoester, respectively.
We calculated the two rate constants from
the excreted fractions observed during the 24
hr after a single oral dose of diester, using
Equations 1 and 2. 
Assuming steady-state intake and meta-
bolic clearance of the diester, the internal
exposure rate for an individual was approxi-
mated by Equation 3 to be: 
[3]
where ME is the urinary concentration of
monoester per g creatinine, CE is the creati-
nine excretion rate normalized by body
weight, f is the ratio of urinary excretion to
total elimination (ku/ktotal), and MWd and
MWm are the molecular weights of the di-
and monoesters, respectively. 
Table 1 shows total fractional excretion
(FE) and fractional urinary excretion of
monoester (FU) during 24 hr after a single
oral dose of diester.
Statistical methods. Linear models are a
common means of analyzing data to detect
statistically significant differences between
groups or for signiﬁcant trends in the data as
a function of some continuous variable. Let
X denote the random variable associated
with the daily intake level calculated using
Equation 3 in a given individuals. For the
analysis presented here, we assume that
Y = ln (X) = fµ(θ) + ε, [4]
where ln denotes the natural log of X, fµ (θ)
is a function of a set of covariates denoted θ,
and, depending on a set of parameters, µ,
and ε is a random variable for which
ε ~ N (0, σ2) [5]
—that is, ε is normally distributed with
mean 0 and variance σ2. From Equation 4,
it follows that
E[Y] = f µ(θ). [6]
In the analysis that follows, we use a linear
model to analyze the impact of age, sex, eth-
nicity, residence, family income, and educa-
tion on the daily intake of phthalates in the
sampled population. The largest model used
was of the form
[7]
where µ0 is the overall mean of the entire
sample, µi is an adjustment to this mean for
the ith demographic indicator θi. Six demo-
graphic indicators were included: µ1θ1 for
age, µ2θ2 for sex, µ3θ3 for ethnicity, µ4θ4 for
residence, µ5θ5 for family income, and µ6θ6
for education.
The parameters µ0, µ1, … µ6, and σ
were estimated via maximum likelihood esti-
mation using the log-likelihood 
[8]
where n is the sample size (n = 289 for the
phthalates example), φ(z; µ, σ2) is the den-
sity function for the normal distribution
with mean µ and variance σ2 evaluated at z,
Φ(z; µ,σ2) is the cumulative density function
for the normal distribution with mean µ and
variance σ2 evaluated at z—i.e., φ (z; µ,σ2) is
Pr[Z < z] where Z is a normal random vari-
able with mean µ and variance σ2, I>LOD is
an indicator function such that I>LOD = 1 if
the observed urinary metabolite can be
quantified, and I>LOD = 0 if it is below the
limit of detection, yi is the log of the daily
intake level for the ith individual and LODi
is the log of the limit of detection for the ith
individual calculated as daily intake level.
We performed the regression analysis
using the LIFEREG procedure in SAS 8.0
for Windows (SAS Institute, Cary, NC) to
test for significant differences in mean
phthalate levels as a function of age, sex, eth-
nicity, residency, family income, and educa-
tion level to phthalate exposure data. The
parameters are estimated by maximum likeli-
hood in LIFEREG procedure, and probabil-
ity density function is used if the observed
urinary metabolite can be quantified, or
cumulative density function is used if it is
below the limit of detection (8). We con-
ducted this analysis using an unweighted
analysis where phthalate distributions were
estimated with changes in the means of these
distribution as a function of demographic
variables. We estimate phthalates exposures
using a weighted prediction for the general
population in which weights were assigned
for subset of the population depending on
the frequency of their demographic variables
in the general U.S. population. In this analy-
sis, a composite distribution is formed by
resampling from individual distributions for
each signiﬁcant demographic variable. 
Results
As an initial step, we calculated correlations
across phthalates and demographic factors.
Within exposure estimates for phthalates,
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Table 1. Total fractional excretion (FE) and fractional urinary excretion of monoester (FU) during 24 hr
after a single oral dose of diester.
Monoester Diester FE FU
Ethyl (MEP) Diethyl (DEP) 0.94a 0.52a
n-Butyl (MBP) Di-n-butyl (DBP) 0.94 0.52 (10,11)
Benzyl (MBzP) n-Butyl benzyl (BBP) 0.70 0.36 (12–14)
Cyclohexyl (MCHP) Dicyclohexyl (DCHP) 0.65b 0.069b
2-Ethylhexyl (MEHP) Di(2-ethylhexyl) (DEHP) 0.65 0.069 (15,16)
n-Octyl (MOP) Di-n-octyl (DOP) 0.65b 0.043 (17)
i-Nonyl (MINP) Di-i-nonyl (DINP) 0.65b 0.069b
aAssumed to be the same as di-n-butyl phthalate. bAssumed to be the same as di(2-ethylhexyl) phthalate. DBP was highly correlated with BBP (r =
0.52, p < 0.01). We noticed relatively low
correlation between BBP and DEHP (r =
0.28, p < 0.01). DBP showed a slight corre-
lation with DCHP (r = 0.13, p = 0.02),
DEHP (r = 0.19, p < 0.01), and DOP (r =
0.13, p = 0.02); BBP with DCHP (r = 0.12,
p = 0.02) and DOP (r = 0.13, p = 0.01); and
DCHP with DEHP (r = 0.11, p = 0.04),
DOP (r = –0.14, p = 0.01), and DINP (r =
0.19, p < 0.01). Also, we noticed a slight
correlation between DEP and DBP (r =
0.18) and between DOP and DINP (r =
0.15). BBP showed slightly signiﬁcant corre-
lation coefficients with age (r = –0.11, p =
0.04), family income (r = 0.17, p < 0.01),
and education level (r = –0.16, p < 0.01);
DCHP with education level (r = 0.12, p =
0.03); DEHP with sex (r = –0.13, p = 0.02),
Mexican ethnicity (r = 0.11, p = 0.04), resi-
dency (r = –0.13, p = 0.01), and family
income (r = 0.14, p = 0.01). There was a
similar magnitude of correlation between
DINP and education level (r = –0.12, p =
0.04), and DBP and education level (r =
–0.13, p = 0.02). The reference values are
male in sex, non-black in black ethnicity,
non-Mexican in Mexican ethnicity, urban in
residency, more than $1,500 in the month
before sampling in family income, and high
school diploma or less in education level.
Table 2 shows the results of the regres-
sion analysis using maximum likelihood
methods as described in “Materials and
Methods.” Individuals with only a high
school education had higher levels of DBP
than individuals with education beyond high
school (p < 0.05). Subjects who had family
income less than $1,500 in the month
before sampling and/or only high school
education had higher levels of BBP than
other groupings (p < 0.05). DEHP was
higher in males and/or in urban populations
and/or in people who had family income less
than $1,500 per month (p < 0.05). 
Figure 1 demonstrates the differences
between estimates of DBP in subjects who
had only a high school education or less ver-
sus subjects with education beyond high
school. The ﬁtted normal curve of log DBP
in subjects who had a high school education
or less was signiﬁcantly shifted to right (p =
0.02). There were no censored observations
in these samples, and the results indicate
fairly close agreement between the observed
data and the fitted normal distribution.
Figure 2 illustrates the fit of the normal
curve of log DEHP by residency; here the
distribution was significantly shifted to the
right in subjects who lived in the urban areas
(p = 0.01). The proportion below the LOD
is less in urban (17.7%) than in rural
(27.2%), and both graphs show a consider-
able difference between the observed
histogram and the plotted density due to the
data points below the LOD.
Table 3 shows estimated phthalates
exposure weighted using demographic char-
acteristics in the general U.S. population.
The mean of estimated exposure is 10.1
µg/kg/day for DEP, 1.66 µg/kg/day for
DBP, 0.84 µg/kg/day for BBP, 1.26 × 10–5
µg/kg/day for DCHP, 0.41 µg/kg/day for
DEHP, 6.16 × 10–5 µg/kg/day for DOP,
and 8.99 × 10–7 µg/kg/day for DINP.
Discussion
Population-based estimates of environmental
exposures using biomarkers can be difﬁcult to
obtain for a variety of reasons, including prob-
lems with limit of detection, under-sampling
of key strata, time between exposure and
sampling, variation across individuals, varia-
tion within individuals, and the ability to
ﬁnd and interpret a given biomarker. In this
article, we present methods for analyzing
biomarkers of exposure using statistical like-
lihoods, weighted sampling, and regression
methods for censored data. Determination
of normal ranges using biomonitoring data
where measurements are below the LOD is a
frequently encountered problem. Data sets
in which concentrations below a ﬁxed value
are undetectable usually fit a normal or log
normal distribution, and more adequate sta-
tistical methods can be used to determine
their normal range. Maximum-likelihood
estimation is a more appropriate statistical
Articles • Exposure estimates for phthalates and demographic factors
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Table 2. Results of the regression analysis using maximum likelihood methods of the relation between the
log of exposure estimates for phthalates and demographic factors.a
Phthalate, covariate Estimate SE χ2 p-Value
DBP
Intercept 7.51 0.07 10555.43 < 0.001
Educationb –0.29 0.13 4.99 0.02
BBP
Intercept 6.81 0.09 5281.21 < 0.001
Family incomec 0.23 0.11 4.07 0.04
Education –0.25 0.12 4.21 0.04
DEHP
Intercept 6.32 0.24 691.17 < 0.001
Sexd –0.61 0.25 5.91 0.01
Residencye –0.65 0.25 6.54 0.01
Family income 0.68 0.25 7.26 0.007
aThese models include demographic factors such as age (continuous), sex (male, female), ethnicity: black (no, yes), eth-
nicity: Mexican (no, yes), residency (urban, rural), family income (≥ $1,500 in the month before sampling, < $1,500 in the
month before sampling), and education level (high school diploma or less, beyond high school). bReference is high
school diploma or less. cReference is ≥ $1,500 in the month. dReference is male. eReference is urban.
Figure 1. The ﬁt of the normal curve to log DBP data by education; the means of these two distributions
are signiﬁcantly different (p = 0.02). Data were analyzed using a linear regression model with maximum
likelihood methods that account for censoring; see equations in text. 
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tmethod for the determination of normal
range from left-censored data (4–7). Any sta-
tistical analysis depends on the assumption
that the data can reasonably be regarded as a
random sample from some underlying distri-
bution. For the present case, data sets are
available that are not left-censored. These
data sets can be used to suggest suitable dis-
tributions for the censored samples, and
techniques for estimation of parameters from
such samples are straightforward. The log-
normal distribution adequately ﬁt these data
(Figure 1) and were used for all of the bio-
markers. In the case of our left-censored
data, we used the corresponding cumulative
probability distributions so that the likeli-
hood functions for models involving cen-
sored data can easily be constructed and
maximized.
Phthalates are used in the manufacture
of a wide range of plastic and nonplastic
products. Most of a phthalate dose is cleared
in 24 hr and completely eliminated in 3–5
days (13,19–22). Because phthalates are
lipophilic (23), it might be predicted that
these compounds would accumulate in fat.
However, with other lipophilic compounds,
such as polychlorinated biphenyls, deposi-
tion of the compound into fat may not
occur until several hours or several months
after dosing (24–26). Because of the rapid
metabolism of phthalates to more polar
metabolites, these compounds are not
sequestered in fat. Phthalates are widely dis-
tributed in the body, with the liver being the
major, initial repository organ. Clearance
from the body is rapid, and there is only a
slight cumulative potential (16). Even
though there is only a slight cumulative
potential, phthalates are found in a wide
variety of extensively used products, have
been identified in all environmental com-
partments, and are a serious concern for the
possibility of adverse effects. The acute toxic-
ity of phthalates is low, with LD50 values
ranging from 0.7 to > 20 g/kg (27); how-
ever, changes in lipid metabolism (28–30),
testicular atrophy (31,32), alterations in
xenobiotic metabolism (33,34), liver peroxi-
some proliferation (35), and carcinogenicity
(36,37) have been observed. Regarding
reproductive and developmental effects,
phthalates vary in potency, with DEHP
being the most potent and DBP and BBP
roughly an order of magnitude less potent
(38–45). 
Another difﬁculty in estimating the envi-
ronmental hazard posed by phthalates is the
lack of sufficient data documenting the
human and wildlife exposure. Furtmann
(46) has suggested that the main source of
phthalates is consumer products, and that as
a result of disposal of these products, there
are considerable phthalate emissions into the
environment. The estimated total loss to the
environment of phthalates in Western
Europe has been estimated as 7,740
tons/annum, or approximately 1% of total
consumption (47). However, the use of such
data in the assessment of environmental haz-
ards for individual chemicals is problematic
because the data are generalized, and esti-
mates refer to total phthalates. Other more
rigorous deterministic approaches based on
measured or estimated levels in environmen-
tal media (food, soil, water, air) and human
activity/consumption patterns have been
used for estimating individual phthalate
exposure (48). Recently, the intake of several
phthalates was estimated from measured
individual urinary phthalate by Kohn et al.
(3) and were found to agree quite well with
previous deterministic exposure estimates
(3). Kohn et al. described in detail how the
different metabolites can be derived from
common precursor compounds or can arise
from different parent compounds. For
MBzP, the presumed parent compound is
BBP; however, MBP has two parent com-
pounds, BBP and DBP. For the other
monoesters, the presumed parent compound
is the diester with two of the same sub-
stituents as in the monoester. Estimates of
exposure from biomarker data are based on
real, not potential, dose, provide informa-
tion on individual variation in exposure, and
allow for a more rigorous evaluation of fac-
tors contributing to exposure. In this study,
we investigated the association between bio-
marker-based exposure estimates for phtha-
lates and demographic factors in a human
reference population. 
Exposure data for phthalates are critical for
scientiﬁcally sound human risk assessments,
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Table 3. Estimated phthalates exposure (µg/kg/day) weighted using demographic characteristics in the
general US population and using regression parameters which are signiﬁcant (p < 0.15) from the LIFEREG
procedure.a
Phthalates Variableb Mean Median 5th percentile 95th percentile
DEP Ethnicity (black) 10.1 10.2 0.43 229
DBP Education, ethnicity  1.66 1.66 0.31 8.78
(Mexican)
BBP Family income, 0.84 0.85 0.19 3.65
education
DCHP Family income 1.26 × 10–5 1.30 × 10–5 1.18 × 10–9 0.14
DEHP Sex, residence,
family income 0.41 0.41 0.015 11.3
DOP Residence, education 6.16 × 10–5 6.26 × 10–5 2.19 × 10–9 1.56
DINP None 8.99 × 10–7 9.28 × 10–7 4.25 × 10–13 1.67
aData from U.S. Census Bureau (18). bBelow 0.15 signiﬁcant level.
Figure 2. The ﬁt of the normal curve to log DEHP data by residency; the means of these two distributions
are signiﬁcantly different (p = 0.01). Data were analyzed using a linear regression model with maximum
likelihood methods that account for censoring; see equations in text.
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Urban
n = 164
Rural
n = 125especially with respect to potentially suscep-
tible populations. Our analysis suggests that
people with a high school education or less
have higher urinary output of DBP and BBP
metabolites; individuals with a family
income less than $1,500 in the month
before sampling have higher urinary output
of BBP and DEHP metabolites; and males
and urban populations have higher urinary
output of DEHP metabolites. The analysis
used assumed that the pharmacokinetics of
these compounds is the same in all individu-
als; this may not be true because genetic
polymorphisms in the genes controlling the
metabolism and elimination of phthalates
may exist and could have an impact on levels
of these metabolites in the urine. Hence, our
findings may derive from differences in
actual exposures, differences in metabolism,
or a combination of these. Further study is
needed to determine which of these may
drive the observed differences.
Our sampled data have strata differences
in demographic factors compared with the
general U.S. population. We found signifi-
cant variables in the regression model using
the LIFEREG procedure weighted toward
minority ethnicity, rural residency, low fam-
ily income, and low education level. We esti-
mated distributions with changes in the
means of these distributions as a function of
the demographic variables. We estimated
phthalate exposures using a weighted predic-
tion for the general population in which
weights were assigned for each subset of the
population depending on the frequency of
their demographic variables in the general
U.S. population. This approach yielded
phthalate exposure estimates for the general
U.S. population, but because the study sam-
ple consisted of 289 noninstitutionalized
adults and was not designed to be represen-
tative of the U.S. population, some bias
might be present in our study. Our calcu-
lated human daily intake estimates are in
good agreement with estimates of Kohn et
al. (3) and exposures for the general popula-
tion estimated by the National Toxicology
Program Center for the Evaluation of Risks
to Human Reproduction (48). Therefore,
we suggest that estimating phthalates expo-
sure for the general U.S. population using
weights of demographic characteristics from
a small, nonrepresentative sample as demon-
strated here can be a useful approach for
evaluating human exposures, but should be
interpreted with caution. We can calculate
the mean and fifth percentile of phthalate
intake estimates using this approach, even
though in some cases 75% of the data is
below the LOD.
The correlation matrix of the log of
exposure estimates for phthalates showed a
high correlation between DBP and BBP
(r = 0.52), indicating potential common
sources of exposure or interacting metabolic
pathways. Blount et al. (2) reported that
MBP and MBzP were present predomi-
nantly as the glucuronide form in urine, so
individual differences in glucuronidation
capacity might affect elimination of these
compounds. This example illustrates one
limitation of biomarkers: It is not possible to
attribute differences in individual biomarker
levels to differences in actual exposure or to
metabolic differences. Also, BBP was moder-
ately correlated with DEHP (r = 0.28).
DEHP, DBP, and BBP are of particular
concern because of their developmental and
reproductive toxicity in animals (38–45).
Therefore, assessments of phthalate health
risks should consider cumulative adverse
effects of DEHP, DBP, and BBP.
Recently, the urinary concentration of
the same seven phthalate monoesters in the
urine analyzed here was reported from 1,029
people as part of the National Health and
Nutritional Examination Survey (NHANES)
(49). Measurement of these metabolites will
be repeated in future NHANES, leading to
larger cumulative sample sizes to be used for
deriving national estimates of both current
exposure levels and exposure trends. The data
available to date show that urinary levels of
MEP, MBzP, MBP from NHANES 1999 are
lower than those from NHANES III. Further
efforts will focus on evaluating the association
between biomarker-based exposure estimates
for phthalates and demographic factors in this
larger human reference population. 
In summary, we developed methods for
analyzing biomarkers of exposure using sta-
tistical likelihoods, weighted sampling, and
regression methods for censored data and
analyzed the association between biomarker-
based exposure estimates for phthalates and
demographic factors in a human reference
population. Our ﬁndings suggest that there
may be signiﬁcant demographic variations in
exposure and/or metabolism of phthalates,
and that health-risk assessments for phtha-
late exposure in humans should consider dif-
ferent potential risk groups. These findings
support and extend previous information on
human phthalate exposure and should prove
useful in accurately quantifying human risk
of exposure to these compounds, identifying
factors contributing to higher exposures and
opportunities for reducing those exposures,
and stimulating additional research on
sources of exposure to phthalates.
REFERENCES AND NOTES
1. Harris CA, Henttu P, Parker MG, Sumpter JP. The estro-
genic activity of phthalate esters in vitro. Environ Health
Perspect 105:802–811 (1997).
2.  Blount BC, Silva MJ, Caudill SP, Needham LL, Pirkle JL,
Sampson EJ, Lucier GW, Jackson RJ, Brock JW. Levels of
seven urinary phthalate metabolites in a human reference
population. Environ Health Perspect 108:979–982 (2000).
3. Kohn MC, Parham F, Masten SA, Portier CJ, Shelby MD,
Brock JW, Needham LL. Human exposure estimates for
phthalates. Environ Health Perspect 108:A440–442 (2000).
4. Tsay JY, Chen IW, Maxon HR, Heminger L. A statistical
method for determining normal ranges from laboratory
data including values below the minimum detectable
value. Clin Chem 25:2011–2014 (1979).
5. Vlachonikolis IG, Marriott FH. Evaluation of censored con-
tanimation data. Food Addit Contam 12:637–644 (1995).
6. Lindsey JK, Byrom WD, Wang J, Jarvis P, Jones B.
Generalized nonlinear models for pharmacokinetic data.
Biometrics 56:81–88 (2000).
7. Burmaster DE, Wilson AM. Fitting second-order ﬁnite mix-
ture models to data with many censored values using max-
imum likelihood estimation. Risk Anal 20:261–271 (2000).
8. Tobin J. Estimation of relationships for limited dependent
variables. Econometrica 26:24–36 (1958).
9. Department of Health and Human Services. National
Center for Health Statistics. Third National Health and
Nutrition Examination Survey, 1988–1994, NHANES III
Laboratory Data File. Public Use Data File Documentation
No. 76200. Hyattsville, MD:Centers for Disease Control
and Prevention, 1996.
10. Tanaka A, Matsumoto A, Yamaha T. Biochemical studies
on phthalic esters. III. Metabolism of dibutyl phthalate
(DBP) in animals. Toxicology 9:109–123 (1978). 
11. Foster PMD, Cook MW, Thomas LV, Walters DG, Gangolli
SD. Differences in urinary metabolic profile from di-n-
butyl phthalate-treated rats and hamsters. A possible
explanation for species differences in susceptibility to
testicular atrophy. Drug Metab Dispos 11:59–61 (1983). 
12. Nativelle C, Picard K, Valentin I, Lhugenot JC, Chagnon
MC. Metabolism of n-butyl benzyl phthalate in the female
Wistar rat. Identiﬁcation of new metabolites. Food Chem
Toxicol 37:905–917 (1999). 
13. Eigenberg DA, Bozigian HP, Carter DE. Distribution,
excretion, and metabolism of butylbenzyl phthalate in the
rat. J Toxicol Environ Health 17:445–456 (1986). 
14. Castle L. Personal communication.
15. Peck CC, Albro PW. Toxic potential of the plasticizer
di(2-ethylhexyl) phthalate in the context of its disposition
and metabolism in primates and man. Environ Health
Perspect 45:11–17 (1982). 
16. Kluwe WM. Overview of phthalate ester pharmacokinet-
ics in mammalian species. Environ Health Perspect
45:3–9 (1982). 
17. Albro PW, Moore B. Identification of the metabolites of
simple phthalate diesters in rat urine. J Chromatogr
94:209–218 (1974).
18. U.S. Census Bureau. Statistical Abstract of the United
States: 2000. Available: http://www.census.gov/statab/www/
[cited 1 August 2001].
19. Williams DT, Blanchfield BJ. The retention, distribution,
excretion and metabolism of dibutyl-7-14C in the rat. J
Agric Food Chem 23:854–858 (1975).
20. Tanaka A, Adachi T, Takahaski T, Yamaha T. Biochemical
studies on phthalic esters. I. Elimination, distribution and
metabolism of di-(2-ethylhexyl) phthalate in rats.
Toxicology 4:253–264 (1975).
21. Daniel JW, Bratt H. The absoption, metabolism and tis-
sue distribution of di(2-ethylhexyl) phthalate in rats.
Toxicology 2:51–65 (1974).
22. Williams DT, Blanchﬁeld BJ. The retention, excretion and
metabolism of di(2-ethylhexyl) phthalate administered
orally to the rat. Bull Environ Contam Toxicol 11:371–378
(1974).
23. Leyder F, Boulanger P. Ultraviolet absorption, aqueous
solubility and octanol-water partition for several phtha-
lates. Bull Environ Contam Toxicol 30:152–157 (1984).
24. Matthews HB, Anderson MW. The distribution and
excretion of 2,4,5,2’,5’-pentachlorobiphenyl in the rat.
Drug Metab Dispos 3:211–219 (1975).
25. Pittman KA, Wiener M, Treble DH. Mirex kinetics in the
rhesus monkey. II. Pharmacokinetic model. Drug Metab
Dispos 4:288–295 (1976).
26. Rozman T, Rozman K, Williams J, Greim H. Enhanced
fecal excretion of mirex in rhesus monkeys by 5% min-
eral oil in the diet. Drug Chem Toxicol 4:251–262 (1981).
27. Autian J. Toxicity and health threats of phthalate esters:
review of the literature. Environ Health Perspect 4:3–26
(1973).
28. Reddy JK, Moody DE, Azarnoff DL, Rao MS. Di-(2-ethyl
Articles • Exposure estimates for phthalates and demographic factors
Environmental Health Perspectives • VOLUME 110 | NUMBER 4 | April 2002 409hexyl) phthalate: an industrial plasticizer induces
hypolipidemia and enhances hepatic catalase and carni-
tine acetyltransferase activities in rats and mice. Life Sci
18:941–946 (1976).
29. Bell FP, Patt CS, Brundage B, Gillies PJ, Phillips WA.
Studies on lipid biosynthesis and cholesterol content of
liver and serum lipoproteins in rats fed various phthalate
esters. Lipids 13:66–74 (1978). 
30. Oishi S, Hiraga K. Effects of monoesters of o-phthalic acid
on serum lipid composition of rats. Toxicol Lett 14:79–84
(1982).
31. Creasy DM, Foster JR, Foster PMD. The morphological
development of di-n-pentyl phthalate induced testicular
atrophy in the rat. J Pathol 139:309–321 (1983).
32. Oishi S, Hiraga K. Testicular atrophy induced by di-2-eth-
ylhexyl phthalate: effect of zinc supplement. Toxicol Appl
Phamacol 70:43–48 (1983).
33. Aitio A, Parkki M, Effect of phthalate esters on drug
metabolizing enzyme activities in rat liver. Arch Int
Pharmacodyn Ther 235:187–195 (1978).
34. Walseth F, Toftgard R, Nilsen OG. Phthalate esters I:
Effects on cytochrome P-450 mediated metabolism in rat
liver and lung, serum enzymatic activities and serum pro-
tein levels. Arch Toxicol 50:1–10 (1982).
35. Moody DE, Reddy JK. Hepatic peroxisome (microbody)
proliferation in rats fed plasticizers and related com-
pounds.Toxicol Appl Pharmacol 45:497–504 (1978).
36. Reddy JK, Azarnoff DL, Hignite CE. Hypolipidaemic
hepatic peroxisome proliferators form a novel class of
chemical carcinogens. Nature 283:397–398 (1980).
37. Kluwe WM, McConnell EE, Huff JE, Haseman JK,
Douglas JF, Hartwell VW. Carcinogenicity testing of
phthalate esters and related compounds by the National
Toxicological Program and the National Cancer Institute.
Environ Health Perspect 45:129–133 (1982).
38. Ema M, Itami T, Kawasaki H. Teratogenic phase speci-
ficity of butyl benzyl phthalate in rats. Toxicology
79:11–19 (1993).
39. Shiota K, Chou MJ, Nishimura H. Embryotoxic effects of
di-2-ethylhexyl phthalate (DEHP) and di-n-butyl phthalate
(DBP) in mice. Environ Res 22:245–253 (1980). 
40. Foster PM, Thomas LV, Cook MW, Gangolli SD. Study of
the testicular effects and changes in zinc excretion pro-
duced by some n-alkyl phthalates in the rat. Toxicol Appl
Pharmacol 54:392–398 (1980). 
41. Heindel JJ, Powell CJ. Phthalate ester effects on rat
Sertoli cell function in vitro: effects of phthalate side
chain and age of animal. Toxicol Appl Pharmacol
115:116–123 (1992). 
42. Gray TJ, Beamand JA. Effect of some phthalate esters
and other testicular toxins on primary cultures of testicu-
lar cells. Food Chem Toxicol 22:123–131 (1984). 
43. Ema M, Harazono A, Miyawaki E, Ogawa Y. Developmental
toxicity of mono-n-benzyl phthalate, one of the major
metabolites of the plasticizer n-butyl benzyl phthalate, in
rats. Toxicol Lett 86:19–25 (1996).
44. Gray LE Jr, Wolf C, Lambright C, Mann P, Price M,
Cooper RL, Ostby J. Administration of potentially antian-
drogenic pesticides (procymidone, linuron, iprodione,
chlozolinate, p,p´-DDE, and ketoconazole) and toxic sub-
stances (dibutyl- and diethylhexyl phthalate, PCB 169,
and ethane dimethane sulphonate) during sexual differ-
entiation produces diverse proﬁles of reproductive mal-
formations in the male rat. Toxicol Ind Health 15:94–118
(1999). 
45. Pirkle JL, Sampson EJ, Needham LL, Patterson DG,
Ashley DL. Using biological monitoring to assess human
exposure to priority toxicants. Environ Health Perspect
103(suppl 3):45–48 (1995). 
46. Furtmann RNK. Phthalates in the aquatic environment.
Report no. 6/93. Brussels:European Chemical Industry
Council (European Council for Plasticisers and
Intermediates), 1996. 
47. ECPI. Phthalate Esters Used in PVC. Assessment of the
Release, Occurrence and Possible Effects of Plasticizers
in the Environment [Partial Copy]. Brussels:European
Chemical Industry Council (European Council for
Plasticisers and Intermediates), 1996. 
48. The National Toxicology Program (NTP) Center for the
Evaluation of Risk to Human Reproduction (CERHR).
Available: http://cerhr.niehs.nih.gov [cited 1 August 2001]. 
49. CDC. National Report on Human Exposure to Environmental
Chemicals. Available: http://www.cdc.gov/nceh/dls/
report/default.htm [cited 1 October 2001].
Articles • Koo et al.
410 VOLUME 110 | NUMBER 4 | April 2002 • Environmental Health Perspectives